NewsSOS
STAAR Surgical shares have fallen 19.9% over the past six months, a performance that trails the S&P 500's 12.8% gain during the same period. The stock currently trades at $21.50 per share.
Analysts at StockStory recommend against buying STAAR Surgical, citing flat revenue over the last two years as a sign of slowing demand.
The company generated $339.6 million in revenue over the past 12 months, a figure that marks it as a small player in a healthcare sector where scale is critical.
Larger competitors benefit from economies of scale, allowing them to spread fixed costs for infrastructure, technology, and administration over higher volumes.
Keep reading